Emergent BioSolutions (NYSE:EBS) is a multinational biopharmaceutical company heaquartered in Rockville, Maryland. Emergent's portfolio of products in development includes preventive and therapeutic products for anthrax and botulism, two top priority ("Category A") bioterrorism agents. The company also has vaccines for typhoid, hepatitis B, and group B streptococcus in development.